These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32491995)

  • 21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and clinical immunotherapy implications of
    Wang Q; Lyu J; Zhang W; Shi F; Ren Y; Mao Q; Liu Y; Li Y; Wang S
    Aging (Albany NY); 2021 Nov; 13(21):24271-24289. PubMed ID: 34747716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
    Li H; Li J; Zhang C; Zhang C; Wang H
    Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
    Morgado M; Sutton MN; Simmons M; Warren CR; Lu Z; Constantinou PE; Liu J; Francis LL; Conlan RS; Bast RC; Carson DD
    Oncotarget; 2016 Mar; 7(12):14871-84. PubMed ID: 26918940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 9-Gene Signature Correlated With CD8
    Yan K; Lu Y; Yan Z; Wang Y
    Front Immunol; 2021; 12():622563. PubMed ID: 34220795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
    Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The density and spatial tissue distribution of CD8
    Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
    J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
    Yusko E; Vignali M; Wilson RK; Mardis ER; Hodi FS; Horak C; Chang H; Woods DM; Robins H; Weber J
    Cancer Immunol Res; 2019 Mar; 7(3):458-465. PubMed ID: 30635271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
    Morgado M; Carson DD
    J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
    Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():721409. PubMed ID: 34795662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer.
    Huang L; Zheng S; Fu J; Zhang M; Ge X; Mu N
    Dis Markers; 2022; 2022():6734105. PubMed ID: 36051359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Predictive Value of
    Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
    Front Immunol; 2021; 12():785526. PubMed ID: 35069558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
    Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
    Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.